Odonate Therapeutics LLC (NASDAQ:ODT) Director Jeff L. Vacirca bought 1,000 shares of the business’s stock in a transaction on Tuesday, December 12th. The shares were acquired at an average cost of $23.30 per share, for a total transaction of $23,300.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Odonate Therapeutics LLC (NASDAQ:ODT) remained flat at $$23.00 during midday trading on Friday. 87,873 shares of the stock were exchanged, compared to its average volume of 330,383. Odonate Therapeutics LLC has a 1-year low of $22.31 and a 1-year high of $24.45.

COPYRIGHT VIOLATION NOTICE: “Odonate Therapeutics LLC (ODT) Director Buys $23,300.00 in Stock” was originally posted by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2017/12/17/odonate-therapeutics-llc-odt-director-buys-23300-00-in-stock.html.

Odonate Therapeutics Company Profile

Odonate Therapeutics, LLC is a pharmaceutical company. The Company is engaged in the development of therapeutics to improve and extend the lives of patients with cancer. It is focused on the development of tesetaxel, a novel chemotherapy agent. It has completed Phase-II studies in patients with metastatic breast cancer (MBC).

Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.